Journal
PATHOGENS
Volume 10, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/pathogens10111377
Keywords
HIV-2; epidemiology; AIDS
Categories
Ask authors/readers for more resources
HIV-2 infection is prevalent in West Africa but also occurs in other parts of the world. It is less transmissible than HIV-1 and has resistance to certain antiretroviral drugs, leading to the risk of misdiagnosis and treatment failures. Clinicians need to consider the possibility of HIV-2 infection in clinical practice to optimize treatment outcomes.
West Africa has the highest prevalence of human immunodeficiency virus (HIV)-2 infection in the world, but a high number of cases has been recognized in Europe, India, and the United States. The virus is less transmissible than HIV-1, with sexual contacts being the most frequent route of acquisition. In the absence of specific antiretroviral therapy, most HIV-2 carriers will develop AIDS. Although, it requires more time than HIV-1 infection, CD4+ T cell decline occurs more slowly in HIV-2 than in HIV-1 patients. HIV-2 is resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and some protease inhibitors. Misdiagnosis of HIV-2 in patients mistakenly considered HIV-1-positive or in those with dual infections can cause treatment failures with undetectable HIV-1 RNA. In this era of global integration, clinicians must be aware of when to consider the diagnosis of HIV-2 infection and how to test for this virus. Although there is debate regarding when therapy should be initiated and which regimen should be chosen, recent trials have provided important information on treatment options for HIV-2 infection. In this review, we focus mainly on data available and on the insight they offer about molecular epidemiology, clinical presentation, antiretroviral therapy, and diagnostic tests of HIV-2 infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available